Research programme: systemic RNAi therapeutics - Alnylam/Arbutus Biopharma

Drug Profile

Research programme: systemic RNAi therapeutics - Alnylam/Arbutus Biopharma

Alternative Names: TKM-ALDH2

Latest Information Update: 28 Feb 2017

Price : $50

At a glance

  • Originator Alnylam Pharmaceuticals; Tekmira Pharmaceuticals Corporation
  • Developer Alnylam Pharmaceuticals; Arbutus Biopharma
  • Class RNA
  • Mechanism of Action Aldehyde dehydrogenase 2 inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alcoholism; Cancer

Most Recent Events

  • 08 Feb 2017 The Supreme Court of British Columbia grants a pre-trial injunction filed against Acuitas Therapeutics by Arbutus Biopharma for Arbutus's lipid nanoparticle (LNP) technology
  • 12 Nov 2012 Alnylam Pharmaceuticals and Tekmira Pharmaceuticals Corporation sign a new licensing agreement regarding RNAi-based therapies, superseding all previous agreements, and resolve all litigation
  • 02 Mar 2012 Preclinical trials in Alcoholism in Canada (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top